Analyst firms · Bernstein · TMO

Bernstein TMO price target and rating history

Thermo Fisher Scientific Inc (TMO) · Industrials

Bernstein rates Thermo Fisher Scientific Inc (TMO) Mkt Perform with a $520 price target, as of its latest action on Jun 26, 2026. It has published 4 rating actions on TMO since September 2023, including 1 upgrade and 1 downgrade. Across 12 firms with a TMO price target in the last 12 months, the median target is $635. Bernstein's $520 is 18% below that.

Current rating
Mkt Perform
Price target
$520
Median target, all firms
$635
Actions on TMO
4

Bernstein price target on TMO

$630$575$520202420252026
Bernstein price target on TMO, each point a stated target, September 2023 to June 2026.

Every Bernstein rating on TMO

How other firms rate TMO

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
UBSBuy$730Sep 9, 2026
CLSAOutperform$748Sep 3, 2026
BernsteinMkt Perform$520Jun 26, 2026
Piper SandlerNeutral$510Jun 11, 2026
HSBCHold$540Jun 3, 2026
Wolfe ResearchOutperform$535Jun 2, 2026
RBC Capital MarketsSector Perform$490May 15, 2026
DZ BankBuy$610Mar 27, 2026
CitigroupBuy$660Dec 11, 2025
Goldman SachsBuy$685Dec 9, 2025
KeyBanc Capital MarketsOverweight$750Dec 8, 2025
Morgan StanleyOverweight$670Dec 2, 2025

Questions about Bernstein and TMO

What is Bernstein's price target for TMO?
Bernstein's latest stated price target for Thermo Fisher Scientific Inc (TMO) is $520, from its action on Jun 26, 2026.
What is Bernstein's rating on TMO?
Bernstein rates TMO Mkt Perform, a neutral rating, as of Jun 26, 2026.
When did Bernstein last change its view on TMO?
On Jun 26, 2026, Bernstein resumes coverage at Mkt Perform, price target $520.
How does Bernstein's TMO target compare with other analysts?
Across 12 firms with a TMO price target in the last 12 months, the median target is $635. Bernstein's $520 is 18% below that.

More TMO rating histories

All Bernstein ratingsTMO news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.